POU5F1 bridges Hedgehog signaling and epithelial remodeling in COPD
- PMID: 40673278
- PMCID: PMC12263618
- DOI: 10.3389/fcell.2025.1566251
POU5F1 bridges Hedgehog signaling and epithelial remodeling in COPD
Abstract
Airway epithelium remodeling is a hallmark of chronic obstructive pulmonary disease (COPD) pathogenesis. Hedgehog signaling is activated during airway epithelial repair to warrant proliferation and during cell differentiation to establish a fully functional epithelium with optimal mucociliary clearance. Consequently, it was found to be altered in COPD patients. Using transcriptomic analysis on air-liquid interface airway epithelial cells during differentiation upon Hedgehog pathway inhibition, we highlighted potential regulators of COPD-associated epithelial remodeling. Furthermore, the alteration of POU5F1 (OCT3/4) was validated in COPD airway epithelial cells and lung tissues. Although further investigations are required, these findings uncovered essential clues tethering respiratory epithelial cell plasticity and Hedgehog signaling.
Keywords: COPD; Hedgehog; Pou5f1; airways; epithelial cells.
Copyright © 2025 Petit, Belgacemi, Mulette, Brisebarre, Saber Cherif, Devilliers, Hatoum, Ancel, Delepine, Durlach, Polette, Deslée, Perotin and Dormoy.
Conflict of interest statement
JA reports receiving grant funds from Amgen France and the Fund for Science and Humanity; receiving personal fees from Roche, Pfizer, MSD, Bristol-Myers Squibb, Novartis, AstraZeneca, Takeda, Sanofi, Regeneron, and Amgen, and receiving support for attending meetings from Roche, Pfizer, MSD, Sanofi, and Regeneron, all of which are outside the scope of this work. GD reports receiving personal fees from Chiesi, receiving personal fees from Boehringer, receiving personal fees from Sanofi, receiving personal fees from GSK, and receiving personal fees from AstraZeneca outside the scope of this work. J-MP reports receiving lecture honoraria from AstraZeneca and receiving support for attending meetings from AstraZeneca and Chiesi, both of which are outside the scope of this work. VD reports receiving personal fees from AstraZeneca outside the scope of this work. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures
References
LinkOut - more resources
Full Text Sources
